SensiScreen Ready-to-use Assays – NRAS 78



SensiScreen FFPE assays are designed for detection of somatic mutations from genomic DNA in solid biopsies (fresh, frozen or FFPE tissue) or other samples with high amounts of DNA (load up to 50 ng). Most SensiScreen FFPE assays are able to robustly detect 0.25-1 % of mutated DNA in a 50 ng wild type DNA background.

SensiScreen assays combine high sensitivity with ease-of-use and are designed to work on standard real-time PCR equipment. Sensitive detection of somatic mutations by SensiScreen is achieved with PentaBase‚ novel and selective INA technologies including the use of BaseBlockers‚ that suppress false positive signals from wild type templates.


SensiScreen assays are supplied as either ‚ úReady-to-use‚ ù or as ‚ úDispense Ready‚ ù mixes. Ready-to-use assays are pre-dispensed in PCR strips and require only addition of gDNA for somatic mutation testing. Dispense-ready mixes include oligonucleotides and master mix in separate tubes ready to be dispensed and added gDNA. The technologies are applicable on standard real-time equipment using standard procedures and results can be ready in less than three hours from receiving a sample (including automated DNA extraction).

Covered Mutations

SensiScreen FFPE assays cover the most common clinically relevant cancer mutations including those in BRAF, EGFR, KRAS and NRAS genes. Explore the mutations below or refer to the Instructions For Use for more details. Please note that all SensiScreen assays are also available for detection in liquid biopsies.

Key features and benefits of SensiScreen FFPE

  • High Sensitivity: Most SensiScreen FFPE assays have a limit of detection between 0.25% and 1% mutant DNA in a wild type background.
  • Easy and fast: Easy to setup (hands-on-time <2 min/sample) and takes less than three hours from sample to result including DNA extraction.
  • State of the art: Based on PentaBase‚ proprietary INA technology. Finds more true mutation positive samples compared to other common methods for somatic mutation testing (Riva et al. 2017).
  • Proven: SensiScreen CE IVD assays are clinically validated in Switzerland and Denmark, and are certified in accordance to the EU guidelines 98/79/EC Medical equipment for in vitro diagnostics.
  • Simplex and multiplex: Supplied in multiplex configurations for mutation screening and simplex configurations for genotyping and monitoring.
  • Open qPCR platform designs: Designed to work on standard real-time PCR instruments and validated on commonly used platforms:.
Rotor-Gene Q (Qiagen) CFX96‚ (Bio-Rad)
MX3000P/3005P (Agilent) ABI 7500/7900HT/QuantStudio‚ 12K Flex (Applied Biosystems)
LightCycler 96 + 480 (Roche) MyGo Pro (IT-IS Life Science)
Mic (Bio Molecular Systems)

Experimental data example

In the figure below is shown published Rotor-Gene 6000 PCR amplification plots of SensiScreen KRAS G12V Simplex and SensiScreen KRAS Exon 2 Multiplex 1 assays using serial dilutions of mutated G12V DNA in a wild type background. 50 ng (about 16.000 copies) of human genomic DNA was added to each reaction. The threshold was set at 10% of the average fluorescence signal of the reference assay at cycle 45. Legend describes the fraction of mutated G12V cell line DNA in a WT background. 0.01% corresponds to 1-2 copies of mutant DNA. For more details on sensitivities of SensiScreen KRAS exon 2 assays, please refer to the publication (Riva et al. 2017) in the resources section.

Country of Origin

Vendor Information

  • Store Name: Pentabase
  • Vendor: Pentabase
  • Address:
  • No ratings found yet!

Product Enquiry